Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression

  • Hindi, Nadia
  • Carrillo-García, Jaime
  • Blanco-Alcaina, Elena
  • Renshaw, Marta
  • Luna, Pablo
  • Durán, José
  • Jiménez, Natalia
  • Sancho, Pilar
  • Ramos, Rafael
  • Moura, David S.
  • Martín-Broto, Javier
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Rhabdomyosarcoma (RMS) in adults is a rare and aggressive disease, which lacks standard therapies for relapsed or advanced disease. This retrospective study aimed to describe the activity of BOMP-EPI (bleomycin, vincristine, methotrexate and cisplatin alternating with etoposide, cisplatin and ifosfamide), an alternative platinum-based regimen, in adult patients with relapsed/metastatic RMS. In the study, 10 patients with RMS with a median age at diagnosis of 20.8 years and a female/male distribution of 6/4 received a mean of 2.5 cycles of BOMP-EPI. The best RECIST response was a complete response in 1/10 (10%) patients, a partial response in 5/10 (50%), stable disease in 3/10 (30%) and progression in 1/10 (10%). With a median follow-up in the alive patients from the start of therapy of 30.5 months (15.7–258), all patients progressed with a median progression-free survival of 8.47 months (95% CI 8.1–8.8), and 7/10 patients died with a median overall survival of 24.7 months (95% CI 13.7–35.6). BOMP-EPI was an active chemotherapy regimen in adults with pediatric-type metastatic RMS, with outcomes in terms of survival that seem superior to what was expected for this poor-prognosis population. Low HMGB1 expression level was identified as a predictive factor of better response to this treatment., The authors thank the Instituto de Salud Carlos III (ISCIII)–Fondo Europeo de Desarrollo Regional (FEDER), project reference PI18/01728. The authors also thank the European Union’s Horizon 2020 research and innovation program, SELNET project No. 825806., This research was funded by IVAN PEREZ grant, GEIS number: GEISBECA2018. D.S.M. received a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A novel nfix-stat6 gene fusion in solitary fibrous tumor, A case report

  • Moura, David S.
  • Díaz-Martín, Juan|||0000-0002-3985-6434
  • Bagué Rosell, Sílvia|||0000-0001-9980-7231
  • Orellana Fernández, Ruth|||0000-0003-1260-7064
  • Sebio, Ana|||0000-0003-3333-2370
  • Mondaza Hernandez, Jose Lucinio|||0000-0002-5642-3796
  • Salguero-Aranda, Carmen
  • Rojo, Federico|||0000-0001-9989-0290
  • Hindi, Nadia|||0000-0002-5864-762X
  • Fletcher, Christopher D.M.
  • Martín Broto, Javier|||0000-0001-7350-6916
Solitary fibrous tumor is a rare subtype of soft-tissue sarcoma with a wide spectrum of histopathological features and clinical behaviors, ranging from mildly to highly aggressive tumors. The defining genetic driver alteration is the gene fusion NAB2-STAT6, resulting from a paracentric inversion within chromosome 12q, and involving several different exons in each gene. STAT6 (sig-nal transducer and activator of transcription 6) nuclear immunostaining and/or the identification of NAB2-STAT6 gene fusion is required for the diagnostic confirmation of solitary fibrous tumor. In the present study, a new gene fusion consisting of Nuclear Factor I X (NFIX), mapping to 19p13.2 and STAT6, mapping to 12q13.3 was identified by targeted RNA-Seq in a 74-year-old female patient diagnosed with a deep-seated solitary fibrous tumor in the pelvis. Histopathologically, the neo-plasm did not display nuclear pleomorphism or tumor necrosis and had a low proliferative index. A total of 378 unique reads spanning the NFIXexon8-STAT6exon2 breakpoint with 55 different start sites were detected in the bioinformatic analysis, which represented 59.5% of the reads intersecting the genomic location on either side of the breakpoint. Targeted RNA-Seq results were validated by RT-PCR/ Sanger sequencing. The identification of a new gene fusion partner for STAT6 in solitary fibrous tumor opens intriguing new hypotheses to refine the role of STAT6 in the sarcomatogenesis of this entity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

  • Hidalgo-Ríos, Samuel
  • Carrillo García, Jaime|||0000-0002-2861-3015
  • Moura, David S.
  • Stacchiotti, Silvia|||0000-0002-1742-8666
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Redondo Sánchez, Andrés|||0000-0002-7257-5642
  • Italiano, Antoine|||0000-0002-8540-5351
  • Gutiérrez, Antonio|||0000-0001-9062-077X
  • Grignani, Giovanni|||0000-0001-5515-569X
  • Hindi, Nadia|||0000-0002-5864-762X
  • López Guerrero, José Antonio|||0000-0002-7369-8388
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Martínez Trufero, Javier|||0000-0002-0997-2573
  • Palmerini, Emanuela|||0000-0003-3406-6705
  • Sebio, Ana|||0000-0003-3333-2370
  • Bernabeu, Daniel|||0000-0003-0828-9104
  • Le Cesne, Axel
  • Casali, Paolo Giovanni|||0000-0003-4056-8023
  • Blay, Jean-Yves|||0000-0001-7190-120X
  • Cruz-Jurado, Josefina|||0000-0001-6398-1641
  • Martín Broto, Javier|||0000-0001-7350-6916
Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16.8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib.